News from the European Society of Cardiology Congress — Physician’s First Watch
News from the European Society of Cardiology Congress
By the NEJM Journal Watch Editors
This weekend, CardioExchange has been reporting news from the European Society of Cardiology Congress in Barcelona, Spain. Here are some highlights:
Odyssey Long Term: In high risk patients, the PCSK9 inhibitor alirocumab was associated with a lower rate of cardiac death, myocardial infarction, and unstable angina requiring hospitalization (1.4% vs. 3% in the placebo group). But the results are a post-hoc analysis of a trial neither designed nor powered to study outcomes, so should be considered preliminary and speculative at best.
CvLPRIT: This open-label, randomized study comparing treatment of the infarct-related artery only with complete revascularization in 296 acute MI patients. At 12 months, there was a large, statistically significant reduction in the incidence of major adverse cardiac events in the complete revascularization group.